Key facts
- byoRNA’s last known valuation is $10.3M (Jan 2026).
- It has raised $3.0M; the latest was Early Stage VC ($1.6M) in Jan 2026.
- Notable investors include IRDI Capital Investissement, BPI Group, BioEconomy Ventures, Cecile Real, Genopole — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for byoRNA
- ·The full record, as it builds
Funding rounds
No funding rounds for byoRNA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About byoRNA
Developer of a bioproduction technology designed to help exploit the therapeutic potential of messenger ribonucleic acid. The company's technology uses eukaryotic cell biofactories to isolate the messenger ribonucleic acid of interest inside a cell compartment where it will be able to accumulate without being degraded, enabling health companies to mass-produce longer, safer, and more efficient therapeutic messenger ribonucleic acids by fermentation and enhance productivity to tackle infectious diseases, cancer, and rare diseases.
- Sector
- Healthcare
- HQ
- Pessac, France
- Founded
- 2022
- Employees
- 13
- Website
- byorna.bio/
- Ownership
- Privately Held (backing)
byoRNA doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in byoRNA shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on byoRNA in its N-PORT filings yet. We sweep new filings monthly.